Evidence map›Paper›PMID 40968087›Full record

ArticleBiomolecules & therapeutics2025

Brazilein Impedes IKK Activation by Disrupting RIPK1 Polyubiquitination, Increasing Apoptotic Susceptibility in Cells with Constitutively Active NF-κB.

Kyeong Ah Park, Hee Sun Byun, Jaehee Ha, Chan Sol Kim, Kyung-Cheol Sohn, Sanghee Shin, Chan-Yong Park, Yeon-Jae Cho, Ill Young Lee, Gang Min Hur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kyeong Ah ParkDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Hee Sun ByunDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Jaehee HaDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Chan Sol KimDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Kyung-Cheol SohnDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Sanghee ShinDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Chan-Yong ParkEco-Friendly New Materials Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
Yeon-Jae ChoEco-Friendly New Materials Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
Ill Young LeeEco-Friendly New Materials Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
Gang Min HurDepartment of Pharmacology and Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ubiquitination of RIPK1 serves as a critical regulatory switch in determining the outcome of prosurvival NF-κB signaling by linking the TNFR1 signaling complex to upstream IKK activation. Therefore, identifying bioactive compounds that modulate RIPK1 ubiquitination has emerged as a promising strategy to enhance the therapeutic efficacy of TNF, particularly in cancers with constitutively active NF-κB signaling. In our previous

Indexed as

BrazileinConstitutive NF-κB activationIKK activationRIPK1 ubiquitinationTNF

Identifiers

PMID40968087
PMCPMC12580646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.